Clinical evaluation of hydroxychloroquine combined with valsartan on treatment of patients with IgA nephropathy
Liang Suren
Chang Jie
Guo Jiayin
Abstract：Objective To observe the clinical effect of hydroxychloroquine combined with valsartan on treatment of patients with IgA nephropathy.Methods A total of 78 patients with IgA nephropathy who were admitted to the First Affiliated Hospital of Henan University of Science&Technology from June 2022 to June 2024 were enrolled in the study and divided into the control group and the experimental group by stratified block randomization,with 39 cases in each group.The control group was treated with basic treatment and valsartan,while the experimental group was given basic treatment,valsartan and hydroxychloroquine,with a treatment course of 24 weeks.The clinical curative effect was observed and compared between the two groups,while the blood pressure,renal function indexes,levels of inflammatory factors and incidence of adverse reactions were compared before and after treatment.Results The total effective rate of the experimental group was 92.31%(36/39),higher than 74.36%(29/39)of the control group,with statistically significant difference(χ2=4.523,P<0.05).There were no statistically significant differences in systolic and diastolic blood pressure((119.74±5.31)mm Hg vs(118.62±5.82)mm Hg(1 mm Hg≈0.133 kPa),(75.62±3.16)mm Hg vs(74.51±3.25)mm Hg)between the two groups after treatment(P>0.05).The post-treatment values of 24-hour urinary protein quantification,blood urea nitrogenand se-rum creatinine of the experimental group were respectively(0.68±0.23)g,(6.10±0.53)mmol·L-1and(93.13±10.72)μmol·L-1,lower than(0.96±0.21)g,(8.18±0.18)mmol·L-1and(98.61±11.89)μmol·L-1 of the control group,with statistically significant difference(t=5.614,23.207,2.138,P<0.05).The estimated glomerular filtration rate was(92.64±8.01)mL·min-1·(1.73 m2)-1 in the experimental group,higher than(88.71±8.42)mL·min-1·(1.73 m2)-1 in the control group(t=2.112,P<0.05).The remission rate of urinary protein was 79.49%(31/39)in the experimental group,higher than48.71%(19/39)in the control group(t=8.023,P<0.05).After treatment,the lev-els of serum tumor necrosis factor-α and interleukin-6 of the experimental group were respectively(24.25±2.73)ng·L-1 and(12.58±2.52)pg·mL-1,lower than(43.66±2.16)ng·L-1 and(16.15±3.57)pg·mL-1 of the control group(t=32.829,5.102,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Hydroxychloroquine com-bined with valsartan can alleviate the renal damage of the IgA nephropathy patients,reduce the proteinuria level,raise the remission rate of urinary protein,inhibit the release of inflammatory factors,and enhance the clinical efficacy.
Keywords：HydroxychloroquineValsartanIgA nephropathyRenal function
Publication Date：2025-08-25
Online Publishing Date：2025-09-01(First online date of this platform, not the publication date of the document)
Pages：4( 839-842 )